Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies
Open Access
- 31 August 2018
- journal article
- research article
- Published by MDPI AG in Antibodies
- Vol. 7 (3) , 35
Abstract
Bispecific antibodies represent an emerging class of antibody drugs that are commonly generated by fusion of Fv or scFv antigen binding domains to IgG or Fab scaffolds. Fv- or scFv-mediated multimerisation of bispecific antibodies via promiscuous vH-vL pairing can result in sub-optimal monomer levels during expression, and hence, undesirable therapeutic protein yields. We investigate the contribution of disulphide stabilised Fv and scFv to Fab-Fv and Fab-scFv multimerisation. We show that monomer levels of isolated Fv/scFv cannot always be used to predict monomer levels of Fab-linked Fv/scFv, and that Fab-scFv monomer levels are greater than the equivalent Fab-Fv. Through grafting bispecifics with framework/CDR-‘swapped’ Fv and scFv, we show that monomer levels of disulphide stabilised Fab-Fv and Fab-scFv can be improved by Fv framework ‘swapping’. The Fab-Fv and Fab-scFv can be considered representative of the significant number of bispecific antibody formats containing appended Fv/scFv, as we also used Fv framework ‘swapping’ to increase the monomer level of an IgG-scFv bispecific antibody. This research may, therefore, be useful for maximising the monomeric yield of numerous pharmaceutically-relevant bispecific formats in pre-clinical development.Keywords
This publication has 24 references indexed in Scilit:
- Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin bindingmAbs, 2016
- Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-lifemAbs, 2016
- Alternative molecular formats and therapeutic applications for bispecific antibodiesMolecular Immunology, 2015
- Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibitionArchives of Biochemistry and Biophysics, 2012
- Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processingProtein Engineering, Design and Selection, 2012
- Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientationProtein Engineering, Design and Selection, 2012
- A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigensmAbs, 2011
- A modular IgG-scFv bispecific antibody topologyProtein Engineering, Design and Selection, 2009
- Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβRmAbs, 2009
- Design and production of novel tetravalent bispecific antibodiesNature Biotechnology, 1997